Connor Clark & Lunn Investment Management Ltd. Sells 7,488 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 43.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,611 shares of the biopharmaceutical company’s stock after selling 7,488 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Intra-Cellular Therapies were worth $803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of ITCI. Avior Wealth Management LLC boosted its holdings in Intra-Cellular Therapies by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 131 shares during the period. M&T Bank Corp boosted its holdings in Intra-Cellular Therapies by 2.2% in the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 141 shares during the period. CIBC Asset Management Inc boosted its holdings in Intra-Cellular Therapies by 5.3% in the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 150 shares during the period. Finally, Pallas Capital Advisors LLC boosted its holdings in Intra-Cellular Therapies by 6.4% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 192 shares during the period. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of NASDAQ ITCI opened at $131.65 on Friday. The firm’s 50-day moving average price is $128.61 and its 200-day moving average price is $97.41. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.32 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on ITCI shares. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Thursday. They set a “hold” rating for the company. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.